By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Chugai Pharmaceutical Co., Ltd. (Japan) 

1-9, Kyobashi 2-chome

Chuo-ku  Tokyo  104-8301  Japan
Phone: 81-3-3281-6611 Fax: 81-3-3281-2828




Company News
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online 7/10/2017 6:47:57 AM
Chugai Pharma''s Bispecific Antibody Emicizumab To Present Results Of Two Pivotal Phase III Studies At ISTH 6/26/2017 6:42:03 AM
Data Of Chugai Pharma's Alecensa Presented At ASCO On Global Phase III ALEX Study 6/6/2017 7:46:50 AM
Results Of The J-ALEX Study For Chugai Pharma's Alecensa Are Published In "The Lancet" Online 5/11/2017 7:10:34 AM
Chugai Pharma's Alecensa Met Its Primary Endpoint In The ALEX Study 4/10/2017 6:18:50 AM
Chugai Pharma - A*STAR Joint Development Project For Anti-Dengue Virus Antibody Selected As Grant Recipient By The GHIT Fund 3/30/2017 6:43:17 AM
Chugai Pharma's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "Nemolizumab (CIM331)" Global Phase II Study Data Published In The New England Journal of Medicine Online 3/2/2017 6:47:14 AM
Chugai Pharma's ALK Inhibitor "Alecensa" Approved In Taiwan 2/27/2017 7:06:16 AM
Chugai Pharma’s ALK Inhibitor "Alecensa" Approved In The EU 2/21/2017 6:26:22 AM
Chugai Pharma's Bispecific Antibody "Emicizumab" For Hemophilia A Meets Primary Endpoint In Phase lll Study 12/22/2016 7:20:31 AM